extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
e274808f19
commit
4acbf79e41
4 changed files with 35 additions and 1 deletions
|
|
@ -23,6 +23,12 @@ The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveragin
|
|||
|
||||
OpenEvidence scale as of January 2026: 20M clinical consultations/month (up from 8.5M in 2025, representing 2,000%+ YoY growth), valuation increased from $3.5B to $12B in months, reached 1M consultations in a single day (March 10, 2026 milestone), used across 10,000+ hospitals. First AI to score 100% on all parts of USMLE. Despite this scale, 44% of physicians remain concerned about accuracy/misinformation and 19% about lack of oversight/explainability—trust barriers persist even among heavy users.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19*
|
||||
|
||||
OpenEvidence reached 20M clinical consultations/month by January 2026 (2,000%+ YoY growth from 8.5M/month in 2025), achieved 1M consultations in a single day on March 10, 2026, and is now valued at $12B (up from $3.5B when the original claim was written). Used across 10,000+ hospitals nationwide. The 40% daily physician usage figure remains accurate but now represents significantly larger absolute scale.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -31,6 +31,12 @@ Abridge raised $300M Series E at $5B valuation and Ambiance raised $243M Series
|
|||
|
||||
OpenEvidence valuation trajectory demonstrates winner-take-most dynamics: $3.5B → $6B → $12B in under 12 months, with $250M Series D led by Thrive Capital and DST Global. This 3.4x valuation increase in months while 35% of healthcare AI deals are flat/down rounds confirms capital concentration in category leaders.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19*
|
||||
|
||||
OpenEvidence valuation tripled from $3.5B to $12B in under 12 months, with a $250M Series D led by Thrive Capital and DST Global in January 2026. The valuation doubled in just 3 months ($6B to $12B), demonstrating extreme capital concentration in the clinical reasoning AI category leader.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -23,6 +23,12 @@ The implication for AI deployment strategy: the highest-value clinical AI applic
|
|||
|
||||
OpenEvidence achieved 100% USMLE score (first AI in history) and is now deployed at 20M consultations/month across 40%+ of US physicians, creating the first large-scale empirical test of whether benchmark performance translates to population health outcomes. The absence of published outcomes data at this deployment scale represents a critical evidence gap—if benchmark performance doesn't translate to clinical impact, we should see evidence of that at 20M monthly consultations.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19*
|
||||
|
||||
OpenEvidence became the first AI to score 100% on all parts of the USMLE, exceeding any human score on the most challenging medical licensing exam. This creates the first real-world test case at scale (20M consultations/month with verified physicians) of whether perfect benchmark performance translates to measurable clinical outcomes. However, no peer-reviewed outcomes data has been published despite this unprecedented scale and benchmark achievement.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -7,13 +7,17 @@ date: 2026-01-01
|
|||
domain: health
|
||||
secondary_domains: [ai-alignment]
|
||||
format: company-announcement
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: medium
|
||||
tags: [openevidence, clinical-ai, decision-support, physician-adoption, clinical-decision-support, health-ai, trust]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-19
|
||||
enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -84,3 +88,15 @@ EXTRACTION HINT: Update the existing claim with scale metrics, but flag the benc
|
|||
- March 10, 2026: OpenEvidence reached 1M consultations in one day
|
||||
- 44% of physicians concerned about OpenEvidence accuracy/misinformation risk
|
||||
- 19% of physicians concerned about lack of physician oversight/explainability
|
||||
|
||||
|
||||
## Key Facts
|
||||
- OpenEvidence reached 8.5M clinical consultations/month in 2025
|
||||
- OpenEvidence reached 20M clinical consultations/month by January 2026
|
||||
- OpenEvidence valuation progression: $3.5B → $6B → $12B in under 12 months
|
||||
- OpenEvidence Series D: $250M led by Thrive Capital and DST Global (January 2026)
|
||||
- OpenEvidence first AI to score 100% on USMLE (all parts)
|
||||
- OpenEvidence used across 10,000+ hospitals and medical centers
|
||||
- March 10, 2026: OpenEvidence reached 1M consultations in one day
|
||||
- 44% of physicians concerned about OpenEvidence accuracy/misinformation risk
|
||||
- 19% of physicians concerned about lack of physician oversight/explainability
|
||||
|
|
|
|||
Loading…
Reference in a new issue